Debiopharm invests in Digital Health
Share this opportunity
Debiopharm’s strategic corporate fund invests in digital health, smart data & innovative tech start-ups
The fund typically invests in Serie A and B rounds, between CHF 3 to 5 million.
Companies that leverage medical data and AI to have an impact on either the patient journey or the development of pharmaceutical products. Debiopharm’s fund is interested for example in real-world data, patient recruitment and adherence
Tools and technologies that add medical value to patient care, such as digital patient monitoring, digital therapeutics, or clinical decision support systems. Consumer products and wellness are outside of the fund’s investment focus.